Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
Short Report
[키워드] ACE2
ACE2 receptor
acting
Activation
acute respiratory distress
addition
anti-inflammatory agents
ARDS
blockade
blood pressure
blood vessels
bradykinin
cause
caused
Cell
cells
clinically
common
coronavirus
cough
COVID-19
COVID-19 pandemic
COVID-19 patient
develop
difficult to breathe
disease
drug
early stage
Endothelial cell
enzyme
Fever
Health
help
Hypothesis
Icatibant
in some
include
Infection
Inflammation
inhibiting
Kinin
leaking
life-threatening
Ligand
Local
Lower
lung
Lungs
mechanical ventilation
mechanism
mice
neutralized
organ
outbreak
oxygen
pathway
patients with COVID-19
plasma
Prevent
PROTECT
Protein
provide
Pulmonary edema
RAAS
receptor
Registered
regulate
responsible
SARS
SARS-CoV-2
SARS-CoV-2 virus
shown
Symptom
syndrome
Treatment
Vascular
vascular leakage
virus
[DOI] 10.7554/eLife.57555 PMC 바로가기 [Article Type] Short Report
[DOI] 10.7554/eLife.57555 PMC 바로가기 [Article Type] Short Report